NCT03907098

Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

A Phase II Study of Endostar in Combination With Chemotherapy in HER-2 Negative Advanced Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying endostar in combination with chemotherapy as a possible treatment for HER-2 negative advanced breast cancer.

Detailed description

This is a multi-center phase II open label single-arm study to assess the safety and efficacy of endostar in combination with chemotherapy for patients with locoregionally recurrent or metastatic HER-2 negative breast cancer. Endostar is an anti-angiogenesis drug. It is prepared by adding 9 amino acids to the N-terminal of the peptide chain on the basis of endostatin. Studies have shown that there may be a synergistic effect between endostar and chemotherapeutic agents.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Endostar	an anti-angiogenesis drug
DRUG	Chemotherapy	Physician's choice

Timeline

• Start date: 2016-06-30
• Primary completion: 2019-12-30
• Completion: 2020-06-30
• First posted: 2019-04-08
• Last updated: 2019-04-08

Locations

1 site across 1 country: China